Back to results
US 7,732,568 B2Granted
Methods for preventing and treating Alzheimer's disease
AssigneeAFFIRIS Forschungs-und Entwicklungs GmbH
InventorFrank Mattner
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for preventing and treating Alzheimer's disease (AD). An Aβ42 mimotope is used for vaccination against AD. The mimotope induces the production of antibodies against Aβ42 but not against the native APP. The mimotope is functionally similar to, but not structurally identical with DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring Aβ42 sequence.
Claims34
An isolated and purified compound, which comprises a sequence selected from the group consisting of EIDYHR (SEQ ID NO:
- 91), ELDYHR (SEQ ID NO:
- 92), EVDYHR (SEQ ID NO:
- 93), DIDYHR (SEQ ID NO:
- 94), DLDYHR (SEQ ID NO:
- 95), DVDYHR (SEQ ID NO:
- 96), DIDYRR (SEQ ID NO:
- 97), DLDYRR (SEQ ID NO:
- 98), DVDYRR (SEQ ID NO:
- 99), DKELRI (SEQ ID NO:
- 100), DWELRI (SEQ ID NO:
- 101), YREFFI (SEQ ID NO:
- 119), YREFRI (SEQ ID NO:
- 102), YAEFRG (SEQ ID NO:
- 103), EAEFRG (SEQ ID NO:
- 104), DYEFRG (SEQ ID NO:
- 105), ELEFRG (SEQ ID NO:
- 106), DRELRI (SEQ ID NO:
- 107), DKELKI (SEQ ID NO:
- 108), DRELKI (SEQ ID NO:
- 109), GREFRN (SEQ ID NO:
- 110), EYEFRG (SEQ ID NO:
- 111), DWEFRDA (SEQ ID NO:
- 112), SWEFRT (SEQ ID NO:
- 113), and SFEFRG (SEQ ID NO:
- 115), wherein said compound binds to an antibody specific for DAEFRH (SEQ ID NO:
- 1) and wherein the compound consists of not more than 15 amino acid residues.
23 more elements
Dependencies are inferred from the claim text.